Icon will this year focus its R&D efforts on gaining new grounds in genomics, said Brian O’Dwyer.Icon
The senior VP for global bioanalytical services spoke to Outsourcing-Pharma about the firm’s role as a contract research organisation (CRO) in the changing landscape of the industry.
He revealed that Icon is also close to completion on a partnership deal with a genomics company.
O’Dwyer told us: “The whole personalised medicine area is a focus of the whole industry.
“Getting drugs that are more targeted will enable sponsors to get drugs approved by the regulators more effectively, and the payers in the industry are going to be supporting drugs that are more efficacious than maybe the prior drugs on the market at the moment.”